Search
Camphor
go.drugbank.com/drugs/DB01744ApprovedInvestigationalWithdrawnCamphor is a bicyclic monoterpene ketone found widely in plants, especially _Cinnamomum camphora_. It is used topically as a skin antipruritic and as an anti-infective agent. … It appears in the list of drug products withdrawn or removed from the market for safety or effectiveness.
Mixtures: DIYENIL 100 ML LOSYON, VİCKS İNHALER 415,4 MG + 415,4 MG/1 G BURUN ÇUBUĞUSynonyms: D-Camphor, Camphor(D)Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in
Products: JAKAVI 20 MG (TABLETS), JAKAVI 20 MG TABLET, 168 TABLETPralatrexate
go.drugbank.com/drugs/DB06813ApprovedInvestigational[A246703] Pralatrexate was approved by the FDA on September 24, 2009. … Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts.
Synonyms: N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid, (2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acidProducts: DIFOLTA 20 MG/ML SOLUCION PARA INFUSION, SOLUTION FOR INFUSION 20MG/MLCinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalCinnarizine could be also viewed as a nootropic drug because of its vasorelaxating abilities (due to calcium channel blockage), which happen mostly in brain. … First synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness.
Mixtures: Arlevert 20 mg/40 mg TablettenProducts: SEFAL FORT 75 MG TABLET, 20 ADET, ULGERON FORT TABLET, 20 ADETGabapentin
go.drugbank.com/drugs/DB00996ApprovedInvestigationalGabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. … stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in
Mixtures: GAVINDO N, Lido GB-300Products: GABAPENTIN EG, Nu-gabapentin CapsulesLacidipine
go.drugbank.com/drugs/DB09236ApprovedIn randomised, well-controlled trials, administration of daily single-dose lacidipine ranging from 2-6 mg demonstrated comparable antihypertensive efficacy similar to that of other long-acting dihydropyridine … It is available as once-daily oral tablets containing 2 or 4 mg of the active compound commonly marketed as Lacipil or Motens. It is not currently FDA-approved.
Products: LACIDIPINA EG, LACIPIL TABLET 4 mgChloral hydrate
go.drugbank.com/drugs/DB01563ApprovedIllicitInvestigationalVet approvedA hypnotic and sedative used in the treatment of insomnia. … The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments.
Products: PMS-CHLORAL HYDRATE SYRUP 500 mg/5 ml, HIDRATO DE CLORAL 10%SOLUCION ORAL(GOTAS)Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigationalChloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. … [A252952] Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a preservative.
Products: Ampres 20 mg/ml Injektionslösung, Ampres 10 mg/ml InjektionslösungTremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.
Products: Imjudo Concentrate for Solution for Intravenous Infusion 20 mg/mL, Imjudo 300 mg/15 ml İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 adetIron Dextran
go.drugbank.com/drugs/DB00893ApprovedInvestigationalVet approvedIron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.
Categories: Compounds used in a research, industrial, or household settingProducts: Endofer 20 Iron dextran 200mg/ml Injectable solution, HEMOFORT 20% INJECTION